Physician profile
Noelle Mooneyham
NPI 1154893477
$596.62
in general payments reported to CMS, 2019-2025
16 companies · $78.61 in 2025
The $78.61 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $43.91 · 2023: $210 · 2024: $82.44 · 2025: $78.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $371.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $96.18 | 2023-2024 | Austedo Xr, Austedo |
| Medline Industries LP | $58.33 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $55.59 | 2023-2024 | Rexulti |
| Exact Sciences Corporation | $51.06 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Evoke Pharma, INC. | $41.97 | 2021-2023 | Gimoti |
| Abbvie INC. | $38.49 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $37.31 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.82 | 2021 | |
| Novo Nordisk INC | $34.14 | 2023-2024 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $28.02 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $25.02 | 2022 | |
| Pfizer INC. | $23.61 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $19.65 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.89 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.82 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $15.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noelle Mooneyham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.